Consensus CorMedix Inc.

Stocks

CRMD

US21900C3088

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2026 am IST			5-day change	1st Jan Change
8.740 ^USD	-2.46%		+4.55%	-24.85%

14/05	CorMedix Inc., Q1 2026 Earnings Call, May 14, 2026
14/05	CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Evolution of the Average Target: CorMedix Inc.

Evolution of the Target Price: CorMedix Inc.

Changes in Analyst Recommendations: CorMedix Inc.

c25d5621c3.af7e8BvcvcYYTYqsj02P9FXxR4l6FVlqHkzSIBxOEj8.NrXzl32a1rR8IdLY-QO4mDnHE_wbRBUJR3qHeCR_WE0rtoGecbnaonNgww~66a6ef644815690f19dfc9d1d54d26d2

Analysts' recommendations: CorMedix Inc.

28/04	RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk	MT
11/02	CorMedix's Growth Outlook Hinges on Trial Data, Prophylaxis Opportunity, RBC Says	MT
21/01	RBC Cuts Price Target on CorMedix to $13 From $22, Keeps Outperform, Speculative Risk	MT
21/25/21	RBC Lifts Price Target on CorMedix to $22 From $21, Keeps Outperform, Speculative Risk	MT
20/25/20	Biopharma firm CorMedix beats Q3 revenue estimates, raises FY guidance	RE
20/25/20	CorMedix Inc. Announces Unaudited Preliminary Revenue Results for the Third Quarter of 2025	CI
29/25/29	Cormedix announces completion of enrollment in phase III Respect clinical trial for Rezzayo	RE
07/25/07	RBC Lifts Price Target on CorMedix to $18 From $17, Keeps Outperform, Speculative Risk	MT
30/25/30	HC Wainwright Initiates Coverage on CorMedix With Buy Rating, $20 Price Target	MT
23/25/23	Needham Raises CorMedix's Price Target to $20 from $15, Keeps Buy Rating	MT
20/25/20	RBC Adjusts Price Target on CorMedix to $17 From $13, Maintains Outperform, Speculative Risk Rating	MT
26/25/26	Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating	MT
07/25/07	Leerink Partners Initiates CorMedix at Outperform With $18 Price Target	MT
19/24/19	RBC Raises Price Target on CorMedix to $12 From $11, Keeps Outperform, Speculative Risk	MT
22/24/22	Truist Raises Price Target on CorMedix to $17 From $12, Keeps Buy Rating	MT
25/24/25	Truist Adjusts CorMedix's Price Target to $12 From $14, Maintains Buy Rating	MT
13/24/13	RBC Trims Price Target on CorMedix to $9 From $10, Keeps Outperform Rating, Speculative Risk Qualifier	MT
15/23/15	RBC Boosts Price Target on CorMedix to $10 From $6 on 'Heightening Prospects of DefenCath Reaching Market,' Keeps Outperform, Speculative Risk	MT
10/23/10	RBC Initiates CorMedix at Outperform, Speculative Risk With $6 Price Target, Sees DefenCath 'More Likely Than Not to Be Approved'	MT
19/23/19	JMP Securities Adjusts Price Target on CorMedix to $19 From $16, Keeps Market Outperform Rating	MT
01/23/01	JMP Securities Adjusts CorMedix's Price Target to $16 From $14, Keeps Market Perform Rating	MT
12/22/12	Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating	MT
09/22/09	JMP Securities Adjusts CorMedix Price Target to $14 From $19, Maintains Market Outperform Rating	MT
09/22/09	Needham Adjusts CorMedix's Price Target to $12 from $20, Keeps Buy Rating	MT
14/21/14	CORMEDIX : Needham & Co Adjusts CorMedix PT to $29 From $31, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' Target price divergence	Objective/dr gap
CORMEDIX INC.		+73.91%
MERCK & CO., INC.		+8.98%
MERCK KGAA		+8.07%
HALOZYME THERAPEUTICS, INC.		+20.72%
KYOWA KIRIN CO., LTD.		-7.97%
SK BIOPHARMACEUTICALS CO., LTD.		+53.38%
YUHAN CORPORATION		+68.54%
BETTA PHARMACEUTICALS CO., LTD.	-	-20.05%
SUPERNUS PHARMACEUTICALS, INC.		+41.48%
Average		+27.45%
Weighted average by Cap.		+9.90%